Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice

By Schreiber Stephan A.   Russmann Anika  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3131-3136

Informa Healthcare

Access to resources Recommend Favorite

Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 202-206

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2063-2071

Informa Healthcare

Access to resources Recommend Favorite

Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Currie Craig J.   McEwan Phil   Poole Chris   Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 967-969

Informa Healthcare

Access to resources Recommend Favorite

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 541-548

John Wiley & Sons Inc

Access to resources Recommend Favorite